NEW YORK – Insurance and retirement planning firm AmeriLife Group has entered into an agreement with DecisionRx to provide Medicare Advantage and Medicare Supplement patients access to the health-tech company's medication therapy optimization (MTO) platform, the companies said Thursday.
AmeriLife Group, which partners with life and health insurance companies, said it expects access to the platform to improve medication efficacy. DecisionRx's MTO platform provides patients and prescribers with recommendations on which drugs are a best fit based on a patient's genetics, lifestyle, and clinical history.
Through the collaboration, AmeriLife will incorporate the MTO platform into its product development and distribution efforts. Patients and prescribers will also be able to work with pharmacists from DecisionRx.
"By integrating comprehensive medication review into our Medicare products, we can ensure our clients receive the most effective and personalized medication regimens," Scotty Elliott, AmeriLife's chief distribution officer of health, said in a statement.
DecisionRx said its services can improve clinical outcomes and reduce healthcare costs by getting patients on medications that they'll be the most responsive and adherent to. The company claims its MTO platform has been linked with reducing healthcare costs by more than $3,600 per Medicare patient per year.